Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 84

1.

Strategies for prevention of gastrointestinal cancers in developing countries: a systematic review.

Shams AZ, Haug U.

J Glob Health. 2017 Dec;7(2):020405. doi: 10.7189/jogh.07.020405.

2.

Assessment of in vivo antimalarial activity of arteether and garlic oil combination therapy.

Palakkod Govindan V, Panduranga AN, Krishna Murthy P.

Biochem Biophys Rep. 2016 Jan 24;5:359-364. doi: 10.1016/j.bbrep.2016.01.015. eCollection 2016 Mar.

3.

Effectiveness of Helicobacter pylori eradication in the prevention of primary gastric cancer in healthy asymptomatic people: A systematic review and meta-analysis comparing risk ratio with risk difference.

Seta T, Takahashi Y, Noguchi Y, Shikata S, Sakai T, Sakai K, Yamashita Y, Nakayama T.

PLoS One. 2017 Aug 17;12(8):e0183321. doi: 10.1371/journal.pone.0183321. eCollection 2017. Review.

4.

Dietary Bioactive Diallyl Trisulfide in Cancer Prevention and Treatment.

Puccinelli MT, Stan SD.

Int J Mol Sci. 2017 Jul 28;18(8). pii: E1645. doi: 10.3390/ijms18081645. Review.

5.

Prevention of Gastric Cancer: Eradication of Helicobacter Pylori and Beyond.

Tsukamoto T, Nakagawa M, Kiriyama Y, Toyoda T, Cao X.

Int J Mol Sci. 2017 Aug 3;18(8). pii: E1699. doi: 10.3390/ijms18081699. Review.

6.

A systematic review and meta-analysis of the role of Helicobacter pylori eradication in preventing gastric cancer.

Rokkas T, Rokka A, Portincasa P.

Ann Gastroenterol. 2017;30(4):414-423. doi: 10.20524/aog.2017.0144. Epub 2017 Apr 7.

7.

Dynamics of Helicobacter pylori infection as a determinant of progression of gastric precancerous lesions: 16-year follow-up of an eradication trial.

Mera RM, Bravo LE, Camargo MC, Bravo JC, Delgado AG, Romero-Gallo J, Yepez MC, Realpe JL, Schneider BG, Morgan DR, Peek RM Jr, Correa P, Wilson KT, Piazuelo MB.

Gut. 2017 Jun 24. pii: gutjnl-2016-311685. doi: 10.1136/gutjnl-2016-311685. [Epub ahead of print]

PMID:
28647684
8.

Helicobacter pylori antibody responses in association with eradication outcome and recurrence: a population-based intervention trial with 7.3-year follow-up in China.

Wang T, Zhang Y, Su H, Li Z, Zhang L, Ma J, Liu W, Zhou T, You W, Pan K.

Chin J Cancer Res. 2017 Apr;29(2):127-136. doi: 10.21147/j.issn.1000-9604.2017.02.05.

9.

The association between vacA or cagA status and eradication outcome of Helicobacter pylori infection: A meta-analysis.

Wang D, Li Q, Gong Y, Yuan Y.

PLoS One. 2017 May 11;12(5):e0177455. doi: 10.1371/journal.pone.0177455. eCollection 2017.

10.

New advances in targeted gastric cancer treatment.

Lazăr DC, Tăban S, Cornianu M, Faur A, Goldiş A.

World J Gastroenterol. 2016 Aug 14;22(30):6776-99. doi: 10.3748/wjg.v22.i30.6776. Review.

11.

Current Perspectives on Gastric Cancer.

Marqués-Lespier JM, González-Pons M, Cruz-Correa M.

Gastroenterol Clin North Am. 2016 Sep;45(3):413-28. doi: 10.1016/j.gtc.2016.04.002. Review.

12.

Cancer prevention and control: alarming challenges in China.

Bode AM, Dong Z, Wang H.

Natl Sci Rev. 2016 Mar;3(1):117-127. Epub 2015 Aug 29.

13.

Genome-wide DNA methylation profiles altered by Helicobacter pylori in gastric mucosa and blood leukocyte DNA.

Zhang Y, Zhang XR, Park JL, Kim JH, Zhang L, Ma JL, Liu WD, Deng DJ, You WC, Kim YS, Pan KF.

Oncotarget. 2016 Jun 14;7(24):37132-37144. doi: 10.18632/oncotarget.9469.

14.

Gastric Cancer: How Can We Reduce the Incidence of this Disease?

den Hoed CM, Kuipers EJ.

Curr Gastroenterol Rep. 2016 Jul;18(7):34. doi: 10.1007/s11894-016-0506-0. Review.

15.

Non-pharmacological treatment of Helicobacter pylori.

Shmuely H, Domniz N, Yahav J.

World J Gastrointest Pharmacol Ther. 2016 May 6;7(2):171-8. doi: 10.4292/wjgpt.v7.i2.171. Review.

16.

Helicobacter pylori Infection Synergistic with IL-1β Gene Polymorphisms Potentially Contributes to the Carcinogenesis of Gastric Cancer.

Hong JB, Zuo W, Wang AJ, Lu NH.

Int J Med Sci. 2016 Apr 8;13(4):298-303. doi: 10.7150/ijms.14239. eCollection 2016. Review.

17.

Diagnosis and management of gastric dysplasia.

Sung JK.

Korean J Intern Med. 2016 Mar;31(2):201-9. doi: 10.3904/kjim.2016.021. Epub 2016 Feb 26. Review.

18.

Establishment and characterisation of patient-derived xenografts as paraclinical models for gastric cancer.

Choi YY, Lee JE, Kim H, Sim MH, Kim KK, Lee G, Kim HI, An JY, Hyung WJ, Kim CB, Noh SH, Kim S, Cheong JH.

Sci Rep. 2016 Mar 1;6:22172. doi: 10.1038/srep22172.

19.

Helicobacter pylori associated gastric intestinal metaplasia: Treatment and surveillance.

Liu KS, Wong IO, Leung WK.

World J Gastroenterol. 2016 Jan 21;22(3):1311-20. doi: 10.3748/wjg.v22.i3.1311. Review.

20.

Mass Eradication of Helicobacter pylorito Prevent Gastric Cancer: Theoretical and Practical Considerations.

Lee YC, Chiang TH, Liou JM, Chen HH, Wu MS, Graham DY.

Gut Liver. 2016 Jan;10(1):12-26. doi: 10.5009/gnl15091.

Supplemental Content

Support Center